A new treatment for Idiopathic Pulmonary Fibrosis using a bispecific antibody.
Official title: A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis
Funded at Virtici, LLC · NIH-11116876 · Data updated 2026-11-12
This study is testing a new treatment called VTC-890 that aims to help people with Idiopathic Pulmonary Fibrosis by blocking two proteins that cause lung scarring, with the hope of improving their breathing and overall health.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virtici, LLC NIH-funded |
| Lab location | 1 site (Seattle, UNITED STATES) |
| Project start | April 1, 2022 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $999,989 |
| NIH project number | 5R44HL164202-04 |
| Project ID | NIH-11116876 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Idiopathic Pulmonary Fibrosis who are experiencing declining lung function.
✕Less likely to help
Patients with other forms of lung disease or those who do not have a diagnosis of Idiopathic Pulmonary Fibrosis may not benefit from this research.
What this research studies
This research focuses on developing a bispecific antibody called VTC-890 that targets two inflammatory proteins involved in Idiopathic Pulmonary Fibrosis (IPF). By blocking these proteins, the treatment aims to reduce lung tissue scarring and improve lung function in patients suffering from this chronic disease. The approach is based on understanding the complex interactions of cytokines that contribute to the progression of IPF. Patients may be monitored for changes in lung function and overall health as part of the treatment process.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that significantly slows the progression of Idiopathic Pulmonary Fibrosis.
How similar studies have gone: While there have been advancements in antifibrotic treatments for IPF, the specific approach of using a bispecific antibody like VTC-890 is novel and has not been extensively tested in this context.
Where this research is happening
-
Virtici, LLC
Seattle, United States Active
Researchers
- Principal investigator: Fanger, Neil a — Virtici, LLC
- Study coordinator: Fanger, Neil a
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Proteomic profile of IPF progression to help tailor treatments
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.